Inventia Life Science’s Post

Advance your cancer research with customizable matrices to more closely mimic the TME! #cancer #cells #cellmodeling #oncology #tme

The comprehensive review of the сurrent ADC landscape and future trends. It seems that this group of oncotherapies could be among the most promising over the next 5 years.

Exciting news! 🙌 A new study on cancer cell extravasation with Cluster PI Prof. Dr. Ute Schepers! The research team developed a multipurpose microfluidic device to reproduce the interactions between cancer cell receptors and their ligands during cancer cell extravasation. This device mimics two crucial aspects of blood vessels: fluid flow to simulate the physiological shear stress induced by blood circulation, and adhesion peptides presented on the channel walls. With a porous fluidic channel, the device can be customized with DNA nanostructures carrying specific nanopatterns of adhesion ligands. Adhesion of circulating tumor cells (CTCs) to the endothelial lining and their subsequent extravasation into surrounding tissues are critical steps for metastatic spreading. They represent some of the most complex events in the metastatic process. This adaptable platform serves as a valuable tool for studying extravasation with precise control over nanoscale molecular patterns. In this way, it helps to better understand the mechanisms of the metastatic process and to identify new targets for cancer therapy. 👉https://lnkd.in/esbX2DKn #paper #3DPrinting #Microfluids #CancerResearch #CellBilogy

𝐖𝐞 𝐭𝐚𝐥𝐤 𝐚 𝐥𝐨𝐭 𝐚𝐛𝐨𝐮𝐭 𝐜𝐞𝐥𝐥-𝐟𝐫𝐞𝐞 𝐃𝐍𝐀 (𝐜𝐟𝐃𝐍𝐀) 𝐚𝐧𝐝 𝐡𝐨𝐰 𝐢𝐭 𝐢𝐬 𝐜𝐫𝐮𝐜𝐢𝐚𝐥 𝐟𝐨𝐫 𝐜𝐚𝐧𝐜𝐞𝐫 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧. 𝐁𝐮𝐭 𝐰𝐡𝐚𝐭 𝐢𝐬 𝐢𝐭? cfDNA consists of DNA fragments that circulate freely in the bloodstream, released from cells through apoptosis (programmed cell death), necrosis (uncontrolled cell death), and active secretion. In cancer, cfDNA can originate from tumor cells, serving as a valuable biomarker for non-invasive cancer detection and monitoring. By analyzing cfDNA, liquid biopsies can detect early cancer signs, monitor tumor evolution, and assess treatment responses. This enables earlier diagnosis, personalized treatment, and real-time monitoring, improving patient outcomes and reducing healthcare costs. At JaxBio, we have developed an ultra-sensitive method for detecting genetic and epigenetic profiles in cfDNA that occurs during cancer initiation and progression > https://lnkd.in/ehPe3p_D #CancerDetection #LiquidBiopsy #CancerResearch #PersonalizedMedicine

A Landscape of Novel Antibody-Drug Conjugates Expands 🚀 Since the first antibody-drug conjugate (ADC) was approved in 2000, the ADC field has seen significant transformation. It has impacted treatment for advanced-stage cancers, including solid tumors. I have recently come across a solid review article where two scientists from Denmark, Virginia Metrangolo and Lars Engelholm delve into the rapid advancements and breakthroughs in ADCs (link in the comments). According to the authors, currently, 14 ADCs are available globally, with over 100 in clinical trials. Notably, 7 ADCs target solid tumors, expanding the range of treatable cancers. This also introduces new possibilities for combination therapies against the toughest cancer types These innovations in design and development make ADCs highly adaptable. ADCs can be precisely tailored to match tumor biology, promising a new era of personalized cancer therapy. The image below summarizes approved and next-generation ADCs and some companies in this space. This insight is part of this week's newsletter, "Where Tech Meets Bio," which has just been sent to its 5K+ email subscribers. Join our community, too! (Link in the comments.) Image provided by Virginia Metrangolo. #antibodydrugconjugates #biotech #biopharmatrend #WhereTechMeetsBio

Breast cancer is a leading cause of cancer-related deaths and 2.3 million new cases are diagnosed each year worldwide. The traditional approach to diagnosing breast cancer relies on immunohistochemistry (IHC), a method that is time-consuming and requires skilled pathologists. However, a recent publication in Biochemistry and Biophysics Reports (https://lnkd.in/e58tZtXt) demonstrates the potential to replace IHC with multiplex qPCR analysis using the four standard biomarkers currently used in IHC: estrogen receptor, progesterone receptor, HER2, and Ki-67 proteins. With the millions of breast cancer screening tests performed each year, high-throughput qPCR technology has the potential to improve breast cancer screening and dramatically decrease the turn-around time and cost, while improving the accuracy of cancer detection. Meridian has created high-concentration and glycerol-free enzymes and master mixes to help high-throughput assay developers reduce manufacturing times and produce user-friendly assays. They are designed to minimize sample variation, reduce background noise, facilitate quicker reactions, and maintain high sensitivity levels. To learn more visit: https://lnkd.in/geimjHW4 #breastcancer #moleculardiagnostics #cancerscreening

Discover what is cell-free DNA (cfDNA) and how it is crucial for cancer detection > #CancerDetection #LiquidBiopsy #CancerResearch #PersonalizedMedicine

🎗 Stand Up to Cancer day 🎗 Last Friday, the world united in the fight against cancer. But the fight doesn't stop on one day — it's ongoing, and every action still counts. At The Electrospinning Company, we're proud to raise awareness of how electrospun materials have and are contributing to advances in cancer research: 🎯 Targeted Drug Delivery: Electrospun nanofibres can deliver anti-cancer drugs directly to tumours, improving effectiveness and reducing side effects 🔬 Tissue Engineering: Electrospun materials can mimic the extracellular matrix, supporting cell growth and tissue repair, supporting post-surgery recovery and wound healing 🧪 Future Potential: Advances in materials science are opening doors to new cancer therapies, like combining electrospinning with heat or magnetic treatments to combat resistant cancer cells We’re excited to see where this research leads and how these versatile materials can help shape the future of cancer treatments! 🌍 #StandUpToCancer #su2c

Using machine learning to improve exosome-based cancer diagnostic: in this pre-print article, Bingrui Li, Fernanda Kugeratski and Kalluri Raghu at MD Anderson Cancer Center presented a novel computational method based on machine learning to differentiate cancers using a panel of exosome-associated proteins https://lnkd.in/e4HD5cx9 Utilising datasets comprising exosome proteins from human cell lines, tissues, plasma, serum, and urine samples across diverse cancers, they identified Clathrin Heavy Chain (CLTC), Ezrin (EZR), Talin-1 (TLN1), Adenylyl cyclase-associated protein 1 (CAP1), and Moesin (MSN) as consistently abundant universal biomarkers for exosomes. They then established three sets of exosome protein panels with pan-cancer applicability, which effectively differentiate cancer-derived exosomes from others and assist in classifying cancer subtypes using random forest models #exosomes #extracellularvesicles #cancerdiagnostic #liquidbiopsy #machinelearning #Vesiculab

We will be present at the conference: Recent insights into Immuno-Oncology (2nd edition) from the VIB where our CDO & Co-Founder Kurt Boonen will present a poster on ImmuneSpec’s advanced immunopeptidomics platform and how our technology leads to the discovery of tumor antigens in needle biopsies. We look forward to the opportunity to elaborate on this topic and get feedback from leading experts in cancer immunotherapy. Please reach-out at: info@immunespec.com if you have interest in getting more information on how our advanced immunopeptidomics technology can support your R&D by identification of tumor antigens, like neoantigens, for development of cancer immunotherapies or for advanced immunogenicity risk assessment which leads to better, safer biotherapeutics! #ImmunoOncology #immunotherapy #tumorantigens #immunopeptidomics